Glucocorticoid induction of occludin expression and endothelial barrier requires transcription factor p54 NONO

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 6, 2013, Pages 4007-4015

  Keil, Jason M ^a   Liu, Xuwen ^a   Antonetti, David A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Blood retinal barrier; Enhancer; Gene expression; Tight junction

Indexed keywords

CLAUDIN 5; GLUCOCORTICOID; OCCLUDIN; POLYPYRIMIDINE TRACT BINDING PROTEIN; POLYPYRIMIDINE TRACT BINDING PROTEIN ASSOCIATED SPLICING FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NONO; TRANSCRIPTION FACTOR P54; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA PURIFICATION; ENDOTHELIUM CELL; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

BLOOD-RETINAL BARRIER; ENHANCER; GENE EXPRESSION; TIGHT JUNCTION;

ANIMALS; BLOOD-RETINAL BARRIER; BLOTTING, WESTERN; CATTLE; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; CLAUDIN-5; DEXAMETHASONE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOTHELIUM, VASCULAR; GENE SILENCING; GLUCOCORTICOIDS; HUMANS; MALE; NUCLEAR MATRIX-ASSOCIATED PROTEINS; OCCLUDIN; OCTAMER TRANSCRIPTION FACTORS; RATS; RETINAL VESSELS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TIGHT JUNCTIONS; TRANS-ACTIVATORS; TRANSFECTION;

EID: 84878999383     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11980     Document Type: Article

References (60)

1. Klein R, Klein BE, Moss SE. The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab Rev. 1989;5:559-570
2. Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev. 2012;12:CD007419
3. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130: 972-979
4. Tsilimbaris MK, Panagiotoglou TD, Charisis SK, Anastasakis A, Krikonis TS, Christodoulakis E. The use of intravitreal etanercept in diabetic macular oedema. Semin Ophthalmol. 2007;22:75-79
5. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125-2132
6. Gillies MC, Simpson JM, Gaston C, et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology. 2009;116:2182-2187
7. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep. 2012;12:364-375
8. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87:24-27
9. Aveleira CA, Lin CM, Abcouwer SF, Ambrosio AF, Antonetti DA. TNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes. 2010;59:2872-2882
10. Zettl KS, Sjaastad MD, Riskin PM, Parry G, Machen TE, Firestone GL. Glucocorticoid-induced formation of tight junctions in mouse mammary epithelial cells in vitro. Proc Natl Acad Sci U S A. 1992;89:9069-9073
11. Romero IA, Radewicz K, Jubin E, et al. Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci Lett. 2003;344:112-116
12. Aijaz S, Balda M, Matter K. Tight junctions: molecular architecture and function. Int Rev Cytol. 2006;248:261-298
13. Antonetti DA, Barber AJ, Khin S, et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content. Diabetes. 1998;47:1953-1959
14. Klaassen I, Hughes JM, Vogels IM, Schalkwijk CG, Van Noorden CJ, Schlingemann RO. Altered expression of genes related to blood-retina barrier disruption in streptozotocininduced diabetes. Exp Eye Res. 2009;89:4-15
15. Morita K, Sasaki H, Furuse M, Tsukita S. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol. 1999;147:185-194
16. Barber AJ, Antonetti DA. Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest Ophthalmol Vis Sci. 2003;44:5410-5416
17. Runkle EA, Antonetti DA. The blood-retinal barrier: structure and functional significance. Methods Mol Biol. 2011;686:133-148
18. Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161:653-660
19. Murakami T, Felinski EA, Antonetti DA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem. 2009;284:21036-21046
20. Murakami T, Frey T, Lin CM, Antonetti DA. Protein kinase Cb phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. Diabetes. 2012;61:1573-1583
21. Hirase T, Staddon JM, Saitou M, et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci. 1997;110:1603-1613
22. Mitic LL, Anderson JM. Molecular architecture of tight junctions. Annu Rev Physiol. 1998;60:121-142
23. Shen L, Weber CR, Raleigh DR, Yu D, Turner JR. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol. 2011;73:283-309
24. Kaal ECA, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol. 2004;16:593-600
25. Heiss JD, Papavassiliou E, Merrill MJ, et al. Mechanism of Dexamethasone suppression of brain tumor-associated vascular permeability in rats. J Clin Invest. 1996;98:1400-1408
26. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RCJ. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem. 2002;80:667-677
27. Forster C, Silwedel C, Golenhofen N, et al. Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system. J Physiol. 2005; 565:475-486
28. Felinski EA, Cox AE, Phillips BE, Antonetti DA. Glucocorticoids induce transactivation of tight junction genes occludin and claudin-5 in retinal endothelial cells via a novel ciselement. Exp Eye Res. 2008;86:867-878
29. Antonetti DA, Wolpert EB. Isolation and characterization of retinal endothelial cells. Methods Mol Med. 2003;89:365-374
30. Phillips BE, Cancel L, Tarbell JM, Antonetti DA. Occludin independently regulates permeability under hydrostatic pressure and cell division in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2008;49:2568-2576
31. Chinnaswamy T, Malik AB, Del Vecchio PJ, Keese CR, Giaver I. Electrical method for detection of endothelial cell shape change in real time: assessment of endothelial barrier function. Proc Natl Acad Sci U S A. 1992;89:7919-7923
32. DeMaio L, Antonetti DA, Scaduto RC Jr, Gardner TW, Tarbell JM. VEGF increases paracellular transport without altering the solvent-drag reflection coefficient. Microvasc Res. 2004;68: 295-302
33. Channa R, Smith M, Campochiaro PA. Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol. 2011; 5:705-713
34. LeHoang P. The gold standard of noninfectious uveitis: corticosteroids. Dev Ophthalmol. 2012;51:7-28
35. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110:1155-1159
36. Zucchiatti I, Lattanzio R, Querques G, et al. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica. 2012;228:117-122
37. Lopez-Quintero SV, Ji XY, Antonetti DA, Tarbell JM. A threepore model describes transport properties of bovine retinal endothelial cells in normal and elevated glucose. Invest Ophthalmol Vis Sci. 2011;52:1171-1180
38. Raleigh DR, Boe DM, Yu D, et al. Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function. J Cell Biol. 2011;193:565-582
39. Bianconcini A, Lupo A, Capone S, et al. Transcriptional activity of the murine retinol-binding protein gene is regulated by a multiprotein complex containing HMGA1, p54 nrb/NonO, protein-associated splicing factor (PSF) and steroidogenic factor 1 (SF1)/liver receptor homologue 1 (LRH-1). Int J Biochem Cell Biol. 2009;41:2189-2203
40. Zhang Z, Carmichael GG. The fate of dsRNA in the nucleus: a p54nrb-containing complex mediates the nuclear retention of promiscuously A-to-I edited RNAs. Cell. 2001;106:465-475
41. Hata K, Nishimura R, Muramatsu S, et al. Paraspeckle protein p54nrb links Sox9-mediated transcription with RNA processing during chondrogenesis in mice. J Clin Invest. 2008;118: 3098-3108
42. Kameoka S, Duque P, Konarska MM. p54nrb associates with the 50 splice site within large transcription/splicing complexes. EMBO J. 2004;23:1782-1791
43. Amelio AL, Miraglia LJ, Conkright JJ, et al. A coactivator trap identifies NONO (p54nrb) as a component of the cAMPsignaling pathway. Proc Natl Acad Sci U S A. 2007;104:20314-20319
44. Dong X, Yu C, Shynlova O, Challis JR, Rennie PS, Lye SJ. p54nrb is a transcriptional corepressor of the progesterone receptor that modulates transcription of the labor-associated gene, connexin 43 (Gja1). Mol Endocrinol. 2009;23:1147-1160
45. Ishitani K, Yoshida T, Kitagawa H, Ohta H, Nozawa S, Kato S. p54nrb acts as a transcriptional coactivator for activation function 1 of the human androgen receptor. Biochem Biophys Res Commun. 2003;306:660-665
46. Mankertz J, Tavalali S, Schmitz H, et al. Expression from the human occludin promoter is affected by tumor necrosis factor a and interferon c. J Cell Sci. 2000;113:2085-2090
47. Sade H, Holloway K, Romero IA, Male D. Transcriptional control of occludin expression in vascular endothelia: Regulation by Sp3 and YY1. Biochim Biophys Acta. 2009; 1789:175-184
48. Runkle EA, Rice SJ, Qi J, et al. Occludin is a direct target of thyroid transcription factor-1 (TTF-1/NKX2-1). J Biol Chem. 2012;287:28790-28801
49. Harke N, Leers J, Kietz S, Drenckhahn D, Forster C. Glucocorticoids regulate the human occludin gene through a single imperfect palindromic glucocorticoid response element. Mol Cell Endocrinol. 2008;295:39-47
50. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41-53
51. Lai CH, Kuo KH. The critical component to establish in vitro BBB model: pericyte. Brain Res Brain Res Rev. 2005;50:258-265
52. Stenman JM, Rajagopal J, Carroll TJ, Ishibashi M, McMahon J, McMahon AP. Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science. 2008;322:1247-1250
53. Alvarez JI, Dodelet-Devillers A, Kebir H, et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science. 2011;334:1727-1731
54. Taddei A, Giampietro C, Conti A, et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol. 2008;10:923-934
55. Yuan L, Le Bras A, Sacharidou A, et al. ETS-related gene (ERG) controls endothelial cell permeability via transcriptional regulation of the claudin 5 (CLDN5) gene. J Biol Chem. 2012;287:6582-6591
56. Fontijn RD, Volger OL, Fledderus JO, Reijerkerk A, de Vries HE, Horrevoets AJ. SOX-18 controls endothelial-specific claudin-5 gene expression and barrier function. Am J Physiol Heart Circ Physiol. 2008;294:H891-H900
57. Sadowska GB, Malaeb SN, Stonestreet BS. Maternal glucocorticoid exposure alters tight junction protein expression in the brain of fetal sheep. Am J Physiol Heart Circ Physiol. 2010; 298:H179-H188
58. Burek M, Forster CY. Cloning and characterization of the murine claudin-5 promoter. Mol Cell Endocrinol. 2009;298: 19-24
59. Kashiwamura Y, Sano Y, Abe M, et al. Hydrocortisone enhances the function of the blood-nerve barrier through the up-regulation of claudin-5. Neurochem Res. 2011;36:849-855
60. Aslam M, Ahmad N, Srivastava R, Hemmer B. TNF-alpha induced NFkappaB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine. 2012;57:269-275.